Key points to consider in the IMPERIAL trial

Affiliations

Comment

Jim A Reekers. Lancet. 2019.

. 2019 Jun 22;393(10190):2489-2490.

doi: 10.1016/S0140-6736(19)30693-2.

¹ Department of Radiology, Academic Medical Center Amsterdam, 1105 AZ Amsterdam, Netherlands. Electronic address: j.a.reekers@amc.uva.nl.

No abstract available

Comment in

Key points to consider in the IMPERIAL trial - Author's reply.
Gray WA; IMPERIAL trial. Gray WA, et al. Lancet. 2019 Jun 22;393(10190):2490. doi: 10.1016/S0140-6736(19)30694-4. Lancet. 2019. PMID: 31232366 No abstract available.

A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, Schroeder H, Prem JT, Holden A, Popma J, Jaff MR, Diaz-Cartelle J, Müller-Hülsbeck S; IMPERIAL investigators. Gray WA, et al. Lancet. 2018 Oct 27;392(10157):1541-1551. doi: 10.1016/S0140-6736(18)32262-1. Epub 2018 Sep 24. Lancet. 2018. PMID: 30262332 Clinical Trial.